
A study links gut E. coli with later UTIs in older women. Understand the risk findings, antibiotic susceptibility results and limits for everyday choices.

On October 27, 2026, University of Washington Medicine reported that gut E. coli carriage was associated with later urinary tract infections in research published in Communications Medicine. The proof-of-concept study also examined whether antibiotic susceptibility results from stool bacteria could anticipate results from bacteria in a later urinary infection.
Before this announcement, researchers were already investigating how microbes living in the gut could become involved in infections elsewhere. The scientific starting point was a distinction between bacterial carriage and disease: finding a microbe in the gut is different from finding it responsible for an infection.
An earlier research announcement from Washington University School of Medicine and Northwestern University illustrates that background. Their separate NIH-supported project is investigating how gut-resident microbes can shift from benign colonizers to disease-causing agents. In this context, a benign colonizer is a microbe that lives in a body site without causing illness there.
That project includes research on E. coli that may become bladder pathogens. Its planned work involves stool and urine sampling alongside mouse models. It is an investigation in progress rather than an announcement of an effective intervention.
The UW Medicine study builds on this interest in the gut as a bacterial reservoir. A reservoir is a place where bacteria reside before potentially becoming relevant to an infection at another site. The new contribution is evidence about whether a gut sample collected before illness holds useful information about a later UTI.
This is one reason research on the wider gut ecosystem involves more than labeling individual bacteria as helpful or harmful. Here, the important questions concern which strains are present and what their presence might indicate over time.
The UW Medicine release describes related but distinct questions. One concerns who later developed a UTI. Another concerns the antibiotic susceptibility of bacteria when a subsequent infection occurred.
According to UW Medicine, researchers analyzed stool samples from 1,804 Seattle-area women aged 50 and older. They then followed participants for 18 months to record later UTI outcomes. This allowed them to compare information collected before an infection with what happened afterward.
The release reports that 90.8% of participants had detectable gut E. coli. During follow-up, 10.9% of participants with detected gut E. coli developed a UTI. The corresponding figure was 3.3% among participants whose stool samples did not reveal the bacterium.
These results connect an earlier gut finding with a later urinary outcome in this cohort. They make the gut reservoir relevant to a forward-looking question: whether information about bacteria present before illness might contribute to future risk assessment.
It matters that the researchers followed participants over time. The comparison was not simply between stool samples taken from people who already had a UTI and samples from people who did not. The gut information came first, with urinary outcomes recorded during follow-up.
UW Medicine also reports that 37.5% of participants carried strains resistant to at least one of the antibiotic groups examined. The release names trimethoprim/sulfamethoxazole, ciprofloxacin and third-generation cephalosporins. These findings concern the properties of the bacteria detected in the study population.
A strain is a particular version of a bacterial species. That distinction matters here because the study examined more than the presence or absence of E. coli. It also considered whether particular bacterial profiles were associated with later outcomes.
The highest reported UTI occurrence was 37.8% among women aged 70 and older who tested positive for the multidrug-resistant strain ST131-H30. The age group and strain identity are essential parts of that finding. They identify the specific subgroup in which the release reported this outcome.
Taken together, the carriage and strain findings suggest that a simple species label may contain less information than a more detailed bacterial profile. That is the research direction described by UW Medicine: investigating whether features of gut bacteria could contribute to more precise assessment.
Antibiotic susceptibility concerns how bacteria respond to an antibiotic. In the UW Medicine release, earlier susceptibility testing of stool E. coli corresponded closely with testing of bacteria from a later urinary infection.
The release reports prediction accuracy ranging from 95% to 100% for that susceptibility comparison. This result addresses a different question from the UTI occurrence figures: how closely an earlier bacterial profile matched the antibiotic response of bacteria found when an infection later developed.
That distinction is central to reading the headline correctly. Infection risk concerns whether illness occurs. Susceptibility concerns the characteristics of bacteria involved in an infection. The study examined both, but they represent different kinds of information for researchers and potentially for future clinical decisions.
The finding therefore adds a treatment-planning research question to the risk-assessment question. Could information collected from the gut before illness eventually help clinicians anticipate which antibiotics are active against bacteria in a later UTI? UW Medicine presents the work as an initial demonstration of that possibility.
Several constraints determine how far these findings reach. They concern the participants studied, the meaning of an association and the evidence needed to turn a research result into a useful clinical approach.
Participants were women aged 50 and older from the Seattle area. They had not had a UTI or received antibiotics for any reason for more than a year before sampling. Those entry conditions are important because they define the population behind the results.
The release does not establish that the findings apply to men or younger adults. It also does not establish applicability to people with recent antibiotic exposure or a recent UTI. Readers concerned about recurrent infections should not assume that this cohort represents their own situation.
The link between gut carriage and later UTI does not establish that carriage alone caused an infection. Nor does ordinary gut E. coli carriage amount to a diagnosis or an indication for antibiotics.
The subgroup finding also needs to remain attached to its specific population. It is not a general estimate for all older women or all people carrying gut E. coli. A striking subgroup result can inform further research without becoming an individual forecast.
The available news release does not provide the full analysis behind the susceptibility-prediction result. It does not state the number of paired stool and urine cases or provide confidence intervals. It also does not identify the specific antibiotics included in that prediction analysis.
Those missing details prevent an independent assessment of how precise or broadly applicable the reported accuracy is. The figure is not an accuracy estimate for predicting who will develop a UTI. It is also not a guarantee of treatment success or a validated performance claim for a consumer stool test.
UW Medicine describes the findings as proof of concept. The release does not establish that this stool-testing approach is clinically available or that using it improves patient outcomes. Demonstrating a useful association and demonstrating better care are separate research tasks.
Senior author Evgeni V. Sokurenko said the findings support investigating resistant bacteria circulating in the community and possible decolonization alongside antibiotic and diagnostic development. Decolonization here means an effort to remove bacterial carriage. His comments describe a research direction rather than evidence that a particular method works.
The study does not establish that foods or consumer gut-health products remove resistant E. coli or prevent UTIs. That includes probiotics and other supplements. When reading information about microbiome-related supplements, the relevant question is whether the claimed intervention was actually tested for the outcome being advertised.
For everyday dietary choices, the proportionate response is continuity rather than a new restriction or a microbiome-targeting shopping list. This study makes the gut reservoir more relevant to infection research. It does not turn ordinary meals into a strategy for eliminating a named bacterium.
The next meaningful advance would be evidence that bacterial profiling improves decisions and health outcomes. Until then, the practical value is a clearer understanding of the research rather than a new food rule. Personal questions about UTI risk, testing or treatment belong with a qualified healthcare professional.
Gut bacteria linked with later infection create a gap between an interesting research signal and a useful reason to choose a supplement. DigestGenius addresses uncertainty about probiotics, prebiotics and fermented foods through free articles and detailed resources that explain the evidence, helping readers distinguish microbiome findings from claims about everyday digestive wellbeing.
DigestGenius publishes research-led guidance on digestion, the gut microbiome, fiber, probiotics, gut-brain signaling, inflammation and everyday digestive wellbeing.



Explore clear, research-led guidance on digestion, the microbiome, food, fiber, probiotics and the gut-brain connection.
read the blog